Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma

In this study, we address one of the major critiques for TIL therapy - the time needed for proper expansion of a suitable product. We postulated that TCR activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and IL-2 would favor preferential expansion of CD...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother
Autori principali: Tavera, René J., Forget, Marie-Andrée, Kim, Young Uk, Sakellariou-Thompson, Donastas, Creasy, Caitlin A., Bhatta, Ankit, Fulbright, Orenthial J., Ramachandran, Renjith, Thorsen, Shawne T., Flores, Esteban, Wahl, Arely, Gonzalez, Audrey M., Toth, Christopher, Wardell, Seth, Mansaray, Rahmatu, Radvanyi, Laszlo G., Gombos, Dan S., Patel, Sapna P., Hwu, Patrick, Amaria, Rodabe N., Bernatchez, Chantale, Haymaker, Cara
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177302/
https://ncbi.nlm.nih.gov/pubmed/29757889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000230
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi